社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
东曜药业-B(01875)
4.820
-0.170
-3.41%
行情数据延迟15分钟
社区
社区
资讯
资讯
资料
资料
公告
公告
最新
推荐
公司概况
公司名称
东曜药业-B
所属市场
SEHK
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.totbiopharm.com.cn
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。
03-31
收购
联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(1)要约结束及要约的结果(2)要约的结算及(3)本公司公众持股量
联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(1)要约结束及要约的结果(2)要约的结算及(3)本公司公众持股量
03-18
年度报告
截至2025年12月31日止年度全年业绩公告
截至2025年12月31日止年度全年业绩公告
03-17
收购
联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；要约已在所有方面成为无条件
联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；要约已在所有方面成为无条件
03-13
收购
联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约(1)于首个截止日期之接纳水平；及(2)要约之延长及经延长时间表
联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约(1)于首个截止日期之接纳水平；及(2)要约之延长及经延长时间表
03-03
收购
有关根据收购守则规则3.8刊发的公告的澄清公告
有关根据收购守则规则3.8刊发的公告的澄清公告
03-01
收购
根据收购守则规则3.8刊发的公告
根据收购守则规则3.8刊发的公告
02-12
收购
东曜药业股份有限公司已发行股本中的普通股之白色股份要约接纳及过户表格
东曜药业股份有限公司已发行股本中的普通股之白色股份要约接纳及过户表格
02-12
收购
东曜药业股份有限公司已授出购股权之粉红色购股权要约接纳及注销表格
东曜药业股份有限公司已授出购股权之粉红色购股权要约接纳及注销表格
02-12
收购
联合公告寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件
联合公告寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件
02-12
收购
综合要约及回应文件花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约
综合要约及回应文件花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约
02-04
收购
联合公告延迟寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件
联合公告延迟寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件
01-19
收购
委任独立财务顾问
委任独立财务顾问
01-14
收购
联合公告(1)花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(2)不可撤销承诺；(3)要约人可能进行的主要交易；(4)药明生物可能进行的须予披露交易；及(5)恢复买卖
联合公告(1)花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(2)不可撤销承诺；(3)要约人可能进行的主要交易；(4)药明生物可能进行的须予披露交易；及(5)恢复买卖
2025-12-31
年度报告
有关截至2024年12月31日止年度的年报的补充公告
有关截至2024年12月31日止年度的年报的补充公告
2025-09-26
半年度报告
2025年中期报告
2025年中期报告
加载更多
分时
5日
日
周
月
数据加载中...
最高
5.060
今开
5.040
量比
0.64
最低
4.810
昨收
4.990
换手率
0.22%
热议股票
{"pagemeta":{"title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东曜药业-B,01875,东曜药业-B股票,东曜药业-B股票老虎,东曜药业-B股票老虎国际,东曜药业-B行情,东曜药业-B股票行情,东曜药业-B股价,东曜药业-B股市,东曜药业-B股票价格,东曜药业-B股票交易,东曜药业-B股票购买,东曜药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东曜药业-B(01875)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东曜药业-B(01875)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}},"tab":"fillings","symbol":"01875","data":{"stockData":{"symbol":"01875","market":"HK","secType":"STK","nameCN":"东曜药业-B","latestPrice":4.82,"timestamp":1775722091608,"preClose":4.99,"halted":0,"volume":1698400,"delay":0,"changeRate":-0.034068136272545076,"floatShares":772787887,"shares":773000000,"eps":-0.15878584933567308,"marketStatus":"未开盘","change":-0.17,"latestTime":"04-09 16:08:11","open":5.04,"high":5.06,"low":4.81,"amount":8319264,"amplitude":0.0501,"askPrice":4.85,"askSize":2800,"bidPrice":4.82,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-0.16520832288794182,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775784600000},"marketStatusCode":0,"adr":0,"listingDate":1573142400000,"exchange":"SEHK","adjPreClose":4.99,"openAndCloseTimeList":[[1775698200000,1775707200000],[1775710800000,1775721600000]],"volumeRatio":0.6367917454176069,"lotSize":400,"spreadScale":0,"tradeCurrency":"HKD"},"tweetData":null,"newsData":null,"noticeData":{"listData":[{"cdn_pdf":true,"hasAttachments":false,"id":"20933933","market":"hk","labels":[],"media":"港交所","original_id":"N.HK4ywUGRcykM","pdf_url":"https://static.tigerbbs.com/ecd361316b8d4b35b2a5e15c153e34c7","pub_time":1774953480000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(1)要约结束及要约的结果(2)要约的结算及(3)本公司公众持股量","symbol":"01875","title":"联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(1)要约结束及要约的结果(2)要约的结算及(3)本公司公众持股量","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0331/2026033102072_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 《收购守则》所指的要约公司刊发的公告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-03-31 18:38","pubTimestamp":1774953480,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20851704","market":"hk","labels":[],"media":"港交所","original_id":"N.HKFbo6YBfn7s","pdf_url":"https://static.tigerbbs.com/2f9b7bce3e0c419e9e0e19021631d8d6","pub_time":1773842160000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"截至2025年12月31日止年度全年业绩公告","symbol":"01875","title":"截至2025年12月31日止年度全年业绩公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0318/2026031801639_c.pdf","us_notice_code":"公告及通告 - [末期业绩]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2026-03-18 21:56","pubTimestamp":1773842160,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20843946","market":"hk","labels":[],"media":"港交所","original_id":"N.HKFTCTVV323C","pdf_url":"https://static.tigerbbs.com/5fb902c28cf8438c9b3401b9d8c082ec","pub_time":1773743520000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；要约已在所有方面成为无条件","symbol":"01875","title":"联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；要约已在所有方面成为无条件","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0317/2026031701217_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 《收购守则》所指的要约公司刊发的公告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-03-17 18:32","pubTimestamp":1773743520,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20829231","market":"hk","labels":[],"media":"港交所","original_id":"N.HK5kpJF7yP32","pdf_url":"https://static.tigerbbs.com/46804957f6f14577be194309817a2ac6","pub_time":1773397800000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约(1)于首个截止日期之接纳水平；及(2)要约之延长及经延长时间表","symbol":"01875","title":"联合公告花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约(1)于首个截止日期之接纳水平；及(2)要约之延长及经延长时间表","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0313/2026031301254_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 《收购守则》所指的要约公司刊发的公告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-03-13 18:30","pubTimestamp":1773397800,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20789824","market":"hk","labels":[],"media":"港交所","original_id":"N.HK4hynXiW5tf","pdf_url":"https://static.tigerbbs.com/80ad78ddaa984f42b8ab631976725e88","pub_time":1772538480000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"有关根据收购守则规则3.8刊发的公告的澄清公告","symbol":"01875","title":"有关根据收购守则规则3.8刊发的公告的澄清公告","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0303/2026030302019_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 有关期权事宜]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-03-03 19:48","pubTimestamp":1772538480,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20780230","market":"hk","labels":[],"media":"港交所","original_id":"N.HK6MGuMHxKL4","pdf_url":"https://static.tigerbbs.com/8455f35b00a7486faa5f961ddea0a2ad","pub_time":1772359860000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"根据收购守则规则3.8刊发的公告","symbol":"01875","title":"根据收购守则规则3.8刊发的公告","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0301/2026030100046_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 有关期权事宜]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-03-01 18:11","pubTimestamp":1772359860,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20726632","market":"hk","labels":[],"media":"港交所","original_id":"N.HKG5bgGaQYJU","pdf_url":"https://static.tigerbbs.com/34da02fc2482451baa03019dbbc1d1fb","pub_time":1770849060000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"东曜药业股份有限公司已发行股本中的普通股之白色股份要约接纳及过户表格","symbol":"01875","title":"东曜药业股份有限公司已发行股本中的普通股之白色股份要约接纳及过户表格","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0212/2026021200044_c.pdf","us_notice_code":"通函 - [《收购守则》所指的受要约公司发出的文件 / 《收购守则》所指的要约公司发出的文件]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-02-12 06:31","pubTimestamp":1770849060,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20726629","market":"hk","labels":[],"media":"港交所","original_id":"N.HKG7vCMLKswY","pdf_url":"https://static.tigerbbs.com/554366b247ca405b8ba9d302a88ad52c","pub_time":1770849060000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"东曜药业股份有限公司已授出购股权之粉红色购股权要约接纳及注销表格","symbol":"01875","title":"东曜药业股份有限公司已授出购股权之粉红色购股权要约接纳及注销表格","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0212/2026021200046_c.pdf","us_notice_code":"通函 - [《收购守则》所指的受要约公司发出的文件 / 《收购守则》所指的要约公司发出的文件]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-02-12 06:31","pubTimestamp":1770849060,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20726628","market":"hk","labels":[],"media":"港交所","original_id":"N.HKDZ7h9TZn6S","pdf_url":"https://static.tigerbbs.com/38bb93486eaa43b79c7dd976979c164b","pub_time":1770849060000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"联合公告寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件","symbol":"01875","title":"联合公告寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0212/2026021200048_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 《收购守则》所指的要约公司刊发的公告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-02-12 06:31","pubTimestamp":1770849060,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20726631","market":"hk","labels":[],"media":"港交所","original_id":"N.HKFq91dFUcde","pdf_url":"https://static.tigerbbs.com/c4e11775e5ae42b39fcb0014d7e3e295","pub_time":1770849000000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"综合要约及回应文件花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约","symbol":"01875","title":"综合要约及回应文件花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0212/2026021200042_c.pdf","us_notice_code":"通函 - [《收购守则》所指的受要约公司发出的文件 / 《收购守则》所指的要约公司发出的文件]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-02-12 06:30","pubTimestamp":1770849000,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20699081","market":"hk","labels":[],"media":"港交所","original_id":"N.HK4ChQFuVnM1","pdf_url":"https://static.tigerbbs.com/54af997c88e84f0999d50ad3804557a0","pub_time":1770213120000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"联合公告延迟寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件","symbol":"01875","title":"联合公告延迟寄发有关花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约的综合文件","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0204/2026020402127_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 《收购守则》所指的要约公司刊发的公告 / 延迟发送通函或其他文件]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-02-04 21:52","pubTimestamp":1770213120,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20643045","market":"hk","labels":[],"media":"港交所","original_id":"N.HK86FmyS5aKJ","pdf_url":"https://static.tigerbbs.com/5ba050c114eb46cf9d341c100bfd82f8","pub_time":1768825500000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"委任独立财务顾问","symbol":"01875","title":"委任独立财务顾问","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0119/2026011900896_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-01-19 20:25","pubTimestamp":1768825500,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20631729","market":"hk","labels":[],"media":"港交所","original_id":"N.HK2Rxk3Y625j","pdf_url":"https://static.tigerbbs.com/66d2dadcbfe24f52b06c83cb9e336dc9","pub_time":1768402320000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"联合公告(1)花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(2)不可撤销承诺；(3)要约人可能进行的主要交易；(4)药明生物可能进行的须予披露交易；及(5)恢复买卖","symbol":"01875","title":"联合公告(1)花旗环球金融亚洲有限公司为及代表要约人就本公司全部已发行股份（要约人及要约人一致行动人士已拥有或同意将予收购的该等股份除外）及注销全部尚未行使购股权而作出的自愿有条件现金要约；(2)不可撤销承诺；(3)要约人可能进行的主要交易；(4)药明生物可能进行的须予披露交易；及(5)恢复买卖","titleType":"收购","type":"hkAnnouncement","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0114/2026011401577_c.pdf","us_notice_code":"公告及通告 - [《收购守则》所指的受要约公司刊发的公告 / 内幕消息 / 复牌]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"交易披露","type_name_en":"Announcement","titleTypeEn":"Acquisition","event_type":"important_notice","event_name":"收购","pubTime":"2026-01-14 22:52","pubTimestamp":1768402320,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20587891","market":"hk","labels":[],"media":"港交所","original_id":"N.HKAp29msuivg","pdf_url":"https://static.tigerbbs.com/be0cc0e9291c4155aa0d18397a8b0c47","pub_time":1767172320000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"有关截至2024年12月31日止年度的年报的补充公告","symbol":"01875","title":"有关截至2024年12月31日止年度的年报的补充公告","titleType":"年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/1231/2025123101356_c.pdf","us_notice_code":"公告及通告 - [末期业绩 / 其他-杂项]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Annual Report","event_type":"important_notice","event_name":"年度报告","pubTime":"2025-12-31 17:12","pubTimestamp":1767172320,"notice_type":"","filling_tag":"","gpt_icon":0},{"cdn_pdf":true,"hasAttachments":false,"id":"20208721","market":"hk","labels":[],"media":"港交所","original_id":"N.HKBnQyypHVmc","pdf_url":"https://static.tigerbbs.com/c1ba97538593410a93926aef1484ed87","pub_time":1758875820000,"showTitleType":false,"size":0,"source":"hk_ex_notice","summary":"2025年中期报告","symbol":"01875","title":"2025年中期报告","titleType":"半年度报告","type":"hkFinancials","url":"https://www.hkexnews.hk/listedco/listconews/sehk/2025/0926/2025092600652_c.pdf","us_notice_code":"财务报表/环境、社会及管治资料 - [中期/半年度报告]","us_title_en":"","is_important":0,"hasEarnInfos":false,"gpt_zh_title":"","gpt_en_title":"","type_name":"财务报告","type_name_en":"Financial Report","titleTypeEn":"Interim Report","event_type":"important_notice","event_name":"半年度报告","pubTime":"2025-09-26 16:37","pubTimestamp":1758875820,"notice_type":"","filling_tag":"","gpt_icon":0}],"currentPage":1,"bottom":false},"companyData":{"profile":{"websiteUrl":"http://www.totbiopharm.com.cn","stockEarnings":[{"period":"1week","weight":-0.036},{"period":"1month","weight":0.1901},{"period":"3month","weight":0.928},{"period":"6month","weight":1.2419},{"period":"1year","weight":2.0506},{"period":"ytd","weight":0.928}],"compareEarnings":[{"period":"1week","weight":0.0253},{"period":"1month","weight":-0.008},{"period":"3month","weight":-0.0183},{"period":"6month","weight":-0.0205},{"period":"1year","weight":0.2708},{"period":"ytd","weight":0.0048}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"东曜药业股份有限公司是一家临床阶段生物制药公司，主要从事开发及商业化肿瘤药物及疗法。该公司的主营业务在中华人民共和国从事抗肿瘤药物的研究与开发、生产及营销、合约开发生产组织（CDMO）/合约生产组织（CMOJ）业务以及自主开发生物药物的对外许可。该公司拥有针对各类癌症的在研肿瘤药物管线，当中包括单克隆抗（mAb）及抗体偶联药物（ADC）。该公司已建立起一个集发现、产程开发、质量管理临床前及临床开发以及商业规模的生产基地和销售及营销能力于一体的综合内部平台。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":0.036017},{"month":2,"riseRate":0,"avgChangeRate":-0.037884},{"month":3,"riseRate":0.571429,"avgChangeRate":0.015652},{"month":4,"riseRate":0.714286,"avgChangeRate":0.050841},{"month":5,"riseRate":0.666667,"avgChangeRate":0.07905},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001367},{"month":7,"riseRate":0.333333,"avgChangeRate":0.023634},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.052288},{"month":9,"riseRate":0.666667,"avgChangeRate":0.011349},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.041625},{"month":11,"riseRate":0,"avgChangeRate":-0.064081},{"month":12,"riseRate":0.714286,"avgChangeRate":0.042078}],"exchange":"SEHK","name":"东曜药业-B","nameEN":"BIODLINK-B"},"aProfile":null}}}